Odonate Therapeutics Can't Beat Investor Suit Over Drug Trial
Odonate Therapeutics Inc. can't shake a proposed securities class action accusing the pharmaceutical company of misleading investors by concealing information on a trial for a chemotherapy agent in development, after a...To view the full article, register now.
Already a subscriber? Click here to view full article